ArticleOpen forum infectious diseases2025
Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among People Who Use Drugs in Turkey.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preoperative Metabolic Risk Factors and Outcomes in Living Donor Liver Transplant in HBV Recipients.Journal of clinical medicine · 2026Article
- Dermatological manifestations among inpatients with substance use disorders: a comparative study of individuals with alcohol and drug use.BMC psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to determine the prevalence of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) in patients who applied to the Alcohol and Substance Abuse Treatment and Education Center and received outpatient or inpatient treatment and to raise awareness among people with these viruses who are unaware of their condition. Methods: The study included 8071 patients whose files were retrospectively scanned via the Healthcare Information Management System for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), hepatitis C virus antibody (anti-HCV), and HIV antibody (anti-HIV) positivity; demographic characteristics; and substance use. Our participants were divided into the people who inject drugs (PWID) and non-injection drug user (NIDU) groups. Results: The mean age of the 8071 patients included in the study was 39.0 ± 12.9 years. The HBsAg, anti-HBs, anti-HCV, and anti-HIV positivity rates were 2.2%, 33.2%, 0.8%, and 0.6%, respectively. In total, 60.9% of the patients were using sedative-hypnotics, 52% methamphetamine, 4.5% alcohol, and 2.8% intravenous substances. In the PWID group, the HBsAg, anti-HCV, and anti-HIV seropositivity rates were 25%, 24.4%, and 10.7%, respectively, and they were significantly higher than those in the NIDU group ( Conclusions: The prevalence of HBV and HCV was similar to the frequency seen in the general population. Ensuring that individuals are aware of their diseases will prevent negative outcomes such as cirrhosis and cancer and contribute to the protection of public health by avoiding person-to-person transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.